Remove IFRS Remove Pharmaceutical Remove Valuation
article thumbnail

Chinese Study highlights limitations on IAS 38, accounting for intangible assets

CFO Talks

The research “How to improve IFRS for intangible assets? Share price : Without a clear reflection of R&D and innovation, the market capitalization could remain lower than it should be, especially for companies in technology, pharmaceuticals, and other high-growth sectors.

article thumbnail

Invisible, yet Invaluable: Valuing Intangibles in the Birkenstock IPO!

Musings on Markets

The resulting debate among accountants about how to bring intangibles on to the books has spilled over into valuation practice, and many appraisers and analysts are wrongly, in my view, letting the accounting debate affect how they value companies.

Valuation 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Musings on Markets: Data Update 5 for 2022: The Bottom Line!

CFO News Room

Even though we live in an age where user platforms and hyper revenue growth can drive company valuations, that adage remains true. IFRS and GAAP now treat as leases as debt, but that is still not the case in many other markets that are not covered by either standard). The numbers yield interesting insights. .

Marketing 130
article thumbnail

Data Update 5 for 2022: The Bottom Line!

Musings on Markets

Even though we live in an age where user platforms and hyper revenue growth can drive company valuations, that adage remains true. IFRS and GAAP now treat as leases as debt, but that is still not the case in many other markets that are not covered by either standard). The numbers yield interesting insights.